This Month in JNM ================= **TSPO PET in neurology:** Vivash and O'Brien focus on new developments, current limitations, and potential future directions in PET imaging of translocator protein expression in neuroinflammation. ***Page [165](http://jnm.snmjournals.org/lookup/volpage/57/165?iss=2)*** **uPAR and glioma imaging:** Hirata and Tamaki offer perspective on the potential of urokinase-type plasminogen activator receptor PET imaging in brain cancer and preview an article in this issue of *JNM* on 2 new uPAR-targeting agents in glioblastoma. ***Page [169](http://jnm.snmjournals.org/lookup/volpage/57/169?iss=2)*** **Molecular imaging in precision medicine:** Ehlerding and Cai describe the potential of multimodality, multiparametric imaging to advance personalized cancer management and preview an article in this issue of *JNM* using such an approach to assess a drug’s biologic effects. ***Page [171](http://jnm.snmjournals.org/lookup/volpage/57/171?iss=2)*** **DNA damage in radioiodine therapy:** Eberlein and colleagues investigate DNA double-strand break formation and its correlation to absorbed dose to the blood in patients with surgically treated differentiated thyroid cancer undergoing a first radioiodine therapy for remnant ablation. ***Page [173](http://jnm.snmjournals.org/lookup/volpage/57/173?iss=2)*** **Triple-phase SPECT/CT in NEN:** Ruf and colleagues compare the commonly used 3-day somatostatin receptor scintigraphy protocol for gastroenteropancreatic neuroendocrine neoplasms with a more patient-friendly 1-day protocol. ***Page [180](http://jnm.snmjournals.org/lookup/volpage/57/180?iss=2)*** **68****Ga-DOTATATE in head and neck PGLs:** Janssen and colleagues compare the clinical utility of 68Ga-DOTATATE PET/CT functional imaging in parasympathetic head and neck paragangliomas with that of anatomic imaging with CT/MR and other functional modalities, including 18F-FDOPA PET/CT. ***Page [186](http://jnm.snmjournals.org/lookup/volpage/57/186?iss=2)*** **Imaging angiogenesis in PAD:** Takagi and colleagues explore the question of whether 99mTc-macroaggregated albumin perfusion scintigraphy can predict quantitated blood flow after therapeutic angiogenesis in patients with peripheral artery disease. ***Page [192](http://jnm.snmjournals.org/lookup/volpage/57/192?iss=2)*** **PVEC in** **18****F-florbetaben PET:** Rullmann and colleagues ask whether partial-volume effect correction, adjusting for neocortical atrophy bias, improves the accuracy of quantitative 18F-florbetaben β-amyloid brain PET imaging. ***Page [198](http://jnm.snmjournals.org/lookup/volpage/57/198?iss=2)*** **11****C-PiB,** **18****F-FDG PET, and AD prediction:** Grimmer and colleagues compare visual and automated techniques in assessment of amyloid deposition (using11C-PiB PET) and neuronal metabolism (using 18F-FDG PET) and resulting accuracies in predicting Alzheimer disease–associated dementia. ***Page [204](http://jnm.snmjournals.org/lookup/volpage/57/204?iss=2)*** **18****F-THK5351 tau PET tracer:** Harada and colleagues detail the development of a novel tau PET tracer designed for imaging neurofibrillary pathology in dementia and describe initial studies in patients with Alzheimer disease. ***Page [208](http://jnm.snmjournals.org/lookup/volpage/57/208?iss=2)*** **Atlas-based attenuation correction:** Sekine and colleagues evaluate a simplified atlas-based attenuation correction method for integrated PET/MR in the human brain by comparing 18F-FDG PET data corrected using either the simplified approach or true CT data. ***Page [215](http://jnm.snmjournals.org/lookup/volpage/57/215?iss=2)*** **Sex-specific brain changes and aging:** Kakimoto and colleagues assess distinctive sex-specific changes in brain glucose metabolism and morphology using MR and 18F-FDG PET imaging during aging in cognitively healthy adults. ***Page [221](http://jnm.snmjournals.org/lookup/volpage/57/221?iss=2)*** **PET uptake time effect on response:** Kurland and colleagues examine the influence of changes in time between tracer injection and 18F-FDG PET image acquisition on tumor response assessment using a virtual clinical trials approach. ***Page [226](http://jnm.snmjournals.org/lookup/volpage/57/226?iss=2)*** **Arsenic trioxide as radiation sensitizer:** Modak and colleagues explore the utility of arsenic trioxide in enhancing the efficacy of 131I-MIBG therapy and test the combination in a trial focusing on recurrent/refractory stage 4 neuroblastoma and metastatic paraganglioma/pheochromocytoma. ***Page [231](http://jnm.snmjournals.org/lookup/volpage/57/231?iss=2)*** **CT dose in PET/CT:** Jallow and colleagues report on diagnostic reference levels of the volumetric CT dose index from sites that conduct whole-body oncologic PET/CT examinations and participated in the scanner validation program of the SNMMI Clinical Trials Network. ***Page [238](http://jnm.snmjournals.org/lookup/volpage/57/238?iss=2)*** **18****F-FIMX modeling:** Zanotti-Fregonara and colleagues evaluate the ability of 18F-FIMX PET to quantify metabotropic glutamate receptor 1 in humans and use the relative density of receptor gene transcripts to estimate specific and nondisplaceable uptake in each brain region. ***Page [242](http://jnm.snmjournals.org/lookup/volpage/57/242?iss=2)*** **CXCR4-directed endoradiotherapy:** Herrmann and colleagues summarize first-in-human experience with chemokine receptor 4–directed endoradiotherapy with 177Lu- and 90Y-pentixather in heavily pretreated patients with intramedullary and extensive extramedullary manifestations of multiple myeloma. ***Page [248](http://jnm.snmjournals.org/lookup/volpage/57/248?iss=2)*** **Gastrointestinal bleeding scintigraphy:** Grady provides an educational overview of the diagnostic uses, appropriate methodologies, interpretive criteria, and special considerations for scintigraphic assessment of gastrointestinal bleeding. ***Page [252](http://jnm.snmjournals.org/lookup/volpage/57/252?iss=2)*** **SSTR agonist vs. antagonist therapy:** Dalm and colleagues directly compare the therapeutic effects of 177Lu-DOTA-octreotate, a somatostatin receptor agonist, and 177Lu-DOTA-JR11, a somatostatin receptor antagonist, in both in vitro and in vivo studies. ***Page [260](http://jnm.snmjournals.org/lookup/volpage/57/260?iss=2)*** **Imaging radiation-induced marrow injury:** Rendon and colleagues use 18F-FLT PET/CT to measure cellular proliferation in bone marrow and ultra-small superparamagnetic iron oxide MR imaging to assess radiation-induced vascular damage for “topological mapping” of radiation exposure and damage. ***Page [266](http://jnm.snmjournals.org/lookup/volpage/57/266?iss=2)*** **uPAR PET in glioblastoma:** Persson and colleagues explore the potential of PET imaging of the urokinase-type plasminogen activator receptor in orthotopic xenografted glioblastoma tumors. ***Page [272](http://jnm.snmjournals.org/lookup/volpage/57/272?iss=2)*** **SPECT and NSC migration:** Cheng and colleagues report on a strategy for mesoporous silica nanoparticle–facilitated SPECT tracking of 111In-labeled neural stem cells and describe the potential for integration with MR for multimodal tracking of therapeutic cells to brain malignancies. ***Page [279](http://jnm.snmjournals.org/lookup/volpage/57/279?iss=2)*** **VEGFR-2 imaging in lung cancer:** Luo and colleagues detail synthesis and characterization of Ramucirumab as part of a 64Cu-labeled antibody-based PET agent for imaging vascular endothelial growth factor receptor 2 expression in vivo. ***Page [285](http://jnm.snmjournals.org/lookup/volpage/57/285?iss=2)*** **Microglial COX-1 in AD:** Shukuri and colleagues describe the synthesis of an 11C-labeled PET probe specific for microglial cyclooxygenase-1 and use it to investigate COX-1 changes during Alzheimer disease progression in a mouse model. ***Page [291](http://jnm.snmjournals.org/lookup/volpage/57/291?iss=2)*** **Cholinesterase visualization in AD:** Macdonald and colleagues report on synthesis and evaluation of a cholinesterase-binding ligand, phenyl 4-123I-iodophenylcarbamate, and its potential to image cholinesterase activity associated with brain β-amyloid plaques. ***Page [297](http://jnm.snmjournals.org/lookup/volpage/57/297?iss=2)*** **Dopamine imaging with** **11****C-6Me*m*Tyr:** Kanazawa and colleagues compare this novel PET probe with β-11C-l-DOPA and 6-18F-fluoro-l-DOPA in quantitative imaging of presynaptic dopamine synthesis in the brains of normal and Parkinson disease model monkeys. ***Page [303](http://jnm.snmjournals.org/lookup/volpage/57/303?iss=2)*** **Imaging metoclopramide transport:** Pottier and colleagues use 11C-metoclopramide PET imaging to elucidate the kinetic impact in the brain of metoclopramide exposure on P-glycoprotein transporter function. ***Page [309](http://jnm.snmjournals.org/lookup/volpage/57/309?iss=2)*** **18****F-labeled deuterated fluorodeprenyl:** Nag and colleagues describe the development of this novel PET agent and initial evaluation of its potential to visualize and quantify monoamine oxidase B activity in vivo. ***Page [315](http://jnm.snmjournals.org/lookup/volpage/57/315?iss=2)*** **Molecular imaging of Src inhibition:** Gao and colleagues use multiple approaches, including bioluminescence, 18F-FDG PET, integrin αvβ3–targeted SPECT/CT, and vascular endothelial growth factor–targeted near-infrared fluorescence imaging, to guide dasatinib anti-Src therapy and aid in rational therapeutic design. ***Page [321](http://jnm.snmjournals.org/lookup/volpage/57/321?iss=2)*** * © 2016 by the Society of Nuclear Medicine and Molecular Imaging, Inc.